Publications by authors named "Mirjam Severs"
Paucity of gastrointestinal plasma cells in common variable immunodeficiency.
Curr Opin Allergy Clin Immunol
December 2024
Purpose Of Review: Common variable immunodeficiency enteropathy (CVID-E) is a noninfectious complication of CVID caused by chronic inflammation of the gastrointestinal (GI) tract. Based on literature, a paucity or lack of plasma cells, although not obligatory for diagnosis, is a pathognomonic feature of CVID and more frequent in CVID-E. However, there is no consensus on standardized histopathological analysis of this feature in biopsies.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers analyzed data from two large studies, finding that male patients generally had earlier onset of CD and more severe disease locations, while female patients had more extraintestinal manifestations (EIMs).
- * Despite these differences in disease characteristics, the study concluded that there were no major variations in treatment management or healthcare costs between male and female IBD patients.
Article Synopsis
- - The study focused on identifying predictors of nonadherence to medical therapy in patients with inflammatory bowel disease (IBD) by assessing various factors over 2.5 years using questionnaires and logistic regression analysis.
- - Among 2,612 patients (1,558 with Crohn's disease and 1,054 with ulcerative colitis), about 12.1% (CD) and 13.3% (UC) were found to be nonadherent to their medication, often involving specific treatments like mesalazine and budesonide.
- - Key predictors of future nonadherence included younger age at diagnosis, the presence of disease flares, feelings of anxiety or depression, and previous nonadherence, suggesting
Background: Capturing (non)-adherence to medical prescriptions in patients with inflammatory bowel disease (IBD) is challenging. We aimed to compare 3 different tools to measure self-assessed medication adherence of patients with IBD.
Methods: Adult patients with Crohn's disease and ulcerative colitis were prospectively followed.
Background: With the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of costs has been observed with medication costs replacing hospitalization and surgery as major cost driver. We aimed to explore the evolution of IBD-related costs over two years of follow-up.
Methods And Findings: In total 1,307 Crohn's disease (CD) patients and 915 ulcerative colitis (UC) patients were prospectively followed for two years by three-monthly web-based questionnaires.
Background: Studies on the costs of health care in patients with inflammatory bowel disease (IBD) are increasingly conducted through the collection of self-reported data. We aimed to assess the concordance between estimated annual costs based on self-reported health care utilization and administrative data in IBD.
Methods: Consecutive patients with Crohn's disease or ulcerative colitis visiting the outpatient clinic were enrolled.
Background And Aims: More data are warranted on the economic impact of different treatment strategies in ulcerative colitis (UC) patients. We compared the costs and quality of life of UC patients with a pouch reconstruction, an ileostomy or anti-tumour necrosis factor α (TNFα) therapy.
Methods: UC patients filled out 3-monthly questionnaires for 2 years.
Background And Aims: Mucosal healing has become the treatment goal in patients with ulcerative colitis (UC) and Crohn's disease (CD). Whether low fecal calprotectin levels and histological healing combined with mucosal healing is associated with a further reduced risk of relapses is unknown.
Methods: Patients with CD, UC or inflammatory bowel disease-unclassified (IBD-U) scheduled for surveillance colonoscopy collected a stool sample prior to bowel cleansing.